Comparison of plasma levels between oral solution and fine granule dosage forms of risperidone

References

• Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry 2001; 62: 153–7
   PubMed Web of Science ®Google Scholar
• Yoshimura R, Nakamura J, Shinkai K, Goto M, Yamada Y, Kaji K, et al. An open study of risperidone liquid in the acute phase of schizophrenia. Hum Psychopharmacol Clin Exp 2005; 20: 243–8
   PubMed Web of Science ®Google Scholar
• Risperdal Package Insert, Janssen Pharmaceutical, K.K., Japan, (in Japanese).
   Google Scholar
• Iwata, N, Kamei, H, Yamanouchi, Y, Naito, H. Objective and subjective assessment of risperidone oral solution as daily medication – Dose antipsychotic formulation effect on adherence to medication?. Jpn J Clin Psychopharmacol 2006;9:1647–52, (in Japanese).
   Google Scholar
• Kobayakawa, H, Fujita, Y, Nakano, K, Shibasaki, C, Hikasa, S, Takebayashi, M. A case showing improvement of both psychotic and extrapyramidal symptoms by switching risperidone tablet to its oral solution. Seishin Igaku 2008;50:375–8, (in Japanese).
   Google Scholar
• Uemura, K, Takahashi, Y, Yasuda, M. Decreased adverse Effects with risperidone oral solution: Report of five cases. Seishin Igaku 2006;48:773–5, (in Japanese).
   Google Scholar
• Takeda, T, Sato, S, Habara, T. Characteristics of risperidone oral solution in the central D2 receptor blockade: A comparison of prolactin responses to the oral solution and the tablet. Jpn J Clin Psychopharmacol 2005;8:1265–71, (in Japanese).
   Google Scholar
• Oshimo, T. Efficacy of undiluted risperidone oral solution administration: Risperidone oral solution may be absorbable through the oral mucosa?. Jpn J Clin Psychopharmacol 2005;8:1273–8, (in Japanese).
   Google Scholar
• Mannens G, Huang M, Meuldermans W, Hendricks J, Woestenborghs R, Heykants J. Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos 1993; 21: 1134–41
   PubMed Web of Science ®Google Scholar
• Yasui-Furukori N, Mihara K, Kondo T, Kubota T, Iga T, Takarada Y, et al. Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia. J Clin Pharmacol 2003; 43: 122–7
   PubMed Web of Science ®Google Scholar
• Chida M, Yokoi T, Nemoto N, Inaba M, Kinoshita M, Kamataki T. A new variant CYP2D6 allele (CYP2D6*21) with a single base insertion in exon 5 in a Japanese population associated with a poor metabolizer phenotype. Pharmacogenetics 1999; 9: 287–93
   PubMedGoogle Scholar
• Ishiguro A, Kubota T, Sasaki H, Yamada Y, Iga T. Common mutant alleles of CYP2D6 causing the defect of CYP2D6 enzyme activity in a Japanese population. Br J Clin Pharmacol 2003; 55: 413–16
   Google Scholar
• Overall JE, Gorham DR. The brief psychiatry rating scale. Psychol Rep 1962; 10: 799–812
   Web of Science ®Google Scholar
• McEvoy JP, Hogarty G.E, Steingard S. Optimal dose of neuroleptic in acute schizophrenia. Arch Gen Psychiatry 1991; 48: 739–45
   PubMed Web of Science ®Google Scholar
• Knegtering R, Baselmans P, Castelein S, Bosker F, Bruggeman R, van den Bosch RJ. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J psychiatry 2005; 162: 1010–12
   PubMed Web of Science ®Google Scholar
• Gutierrez R, Lee PI, Huang ML, Woestenborghs R. Risperidone: Effects of formulations on oral bioavailability. Pharmacotherapy 1997; 17: 599–605
   PubMedGoogle Scholar
• Schotte A, Janssen PFM, Gommeren W, Luyten WHML, Van Gompel P, Lesage AS, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996; 124: 57–73
   PubMed Web of Science ®Google Scholar
• Yoshimura R, Ueda N, Nakamura J. Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Neuropsychobiology 2001; 44: 129–33
   PubMed Web of Science ®Google Scholar
• Jones, B, Smedt, GD, Lemmens, P. Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. Poster at the Congress of the International Academy for Biomedical and Drug Research on Critical Issues in the Treatment of Schizophrenia, 10–12, March, 1995.
   Google Scholar
• Kazamatsuri, H. Tardive dyskinesia: Studies in foreign countries. Seishin Igaku 1971;13:840–55, (in Japanese).
   Google Scholar
• Chien C, Cole JO. Depot phenothiazine treatment in acute psychosis: A sequential comparative clinical study. Am J Psychiatry 1973; 130: 13–18
   PubMed Web of Science ®Google Scholar
• Rifkin A, Quitkin F, Rabiner CJ, Klein DF. Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. Arch Gen Psychiatry 1977; 34: 43–7
   PubMed Web of Science ®Google Scholar
• Farde L, Nordström A, Wiesel F, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 1992; 49: 538–44
   PubMed Web of Science ®Google Scholar
• Remington G, Mamo D, Labelle A, Reiss J, Shammi C, Mannaert E, et al. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry 2006; 163: 396–401
   PubMed Web of Science ®Google Scholar
• Chouinard G, Kopala L, Labelle A, Beauclair L, Johnson SV, Singh KI. Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. Can J Psychiatry 1998; 43: 1018–25
   Google Scholar
• Osawa, T. Experience of high-dose risperidone oral solution for acute psychotic agitation and maintenance in 6 patients with schizophrenia. Jpn J Clin Psychopharmacol 2004;7:1929–34, (in Japanese).
   Google Scholar
• Yoshimura, R, Ueda, N, Ikenouch-Sugita, A, Umene-Nakano, W, Hori, H, Kakihara, S, , et al. Fluctuating plasma levels of the active moiety of risperidone is related to occurrence of extrapyramidal symptoms. Int J Psychiatry Clin Pract 2008; March 2009.
   Google Scholar